KPV (Lys-Pro-Val) is a naturally derived tripeptide corresponding to positions 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino acid neuropeptide produced by the pituitary gland and various peripheral tissues. Despite its small size of just three amino acids, KPV retains the potent anti-inflammatory activity of its parent hormone while lacking alpha-MSH's pigmentation effects. Preclinical research has identified KPV as a powerful inhibitor of NF-kB signaling, a master regulator of inflammatory gene expression, with demonstrated efficacy in animal models of inflammatory bowel disease, contact dermatitis, and bronchial inflammation. Its unique mechanism of action, favorable safety profile in animal studies, and ability to be administered orally have generated significant interest among researchers and the peptide community.
What Is KPV?
KPV is the C-terminal tripeptide fragment of alpha-MSH, consisting of three amino acids: lysine (Lys, K), proline (Pro, P), and valine (Val, V). Its molecular formula is C16H30N4O4, with a molecular weight of 342.43 g/mol, and it is registered under CAS number 67727-97-3.
The discovery of KPV's anti-inflammatory properties emerged from decades of research into alpha-MSH. Beginning in the 1980s, researchers including Anna Catania and James Lipton at Weill Cornell Medical College conducted systematic studies demonstrating that alpha-MSH could reduce fever, suppress inflammatory responses, and modulate immune cell activity far beyond its originally described role in skin pigmentation. The critical breakthrough came when these researchers identified the minimal peptide sequence responsible for anti-inflammatory activity. By testing progressively smaller fragments of alpha-MSH, they determined that the C-terminal tripeptide KPV retained most, and in some cases all, of the parent hormone's anti-inflammatory potency.
This discovery was significant for several reasons. First, KPV's small size makes it far simpler and cheaper to synthesize than full-length alpha-MSH. Second, KPV does not bind to melanocortin receptors and does not increase intracellular cAMP, meaning it delivers anti-inflammatory benefits without the pigmentary or hormonal effects associated with alpha-MSH. Third, as a tripeptide, KPV can be actively transported across cell membranes by the PepT1 di/tripeptide transporter, a property that has major implications for oral bioavailability and targeted delivery to inflamed intestinal tissue.
The primary research-supported properties of KPV include:
- Inhibition of NF-kB inflammatory signaling
- Suppression of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6)
- Reduction of intestinal inflammation via PepT1-mediated cellular uptake
- Anti-inflammatory effects in skin and airway tissue
- Antimicrobial activity against Staphylococcus aureus and Candida albicans
How It Works
NF-kB Pathway Inhibition
The primary mechanism by which KPV exerts its anti-inflammatory effects is through inhibition of nuclear factor-kappa B (NF-kB), one of the most important transcription factors governing inflammatory gene expression. NF-kB controls the transcription of hundreds of genes involved in the inflammatory response, including pro-inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6, as well as chemokines, adhesion molecules, and enzymes like cyclooxygenase-2 (COX-2).
Research has elucidated a specific intracellular mechanism for this effect. In human bronchial epithelial cells, alpha-MSH C-terminal peptides translocate into the cell nucleus and competitively block the interaction between importin-alpha3 (Imp-alpha3) and the p65/RelA subunit of NF-kB. Note that this specific importin-alpha3 mechanism has not been directly demonstrated for KPV itself in a primary peer-reviewed study; it is extrapolated from related alpha-MSH fragment research. Under normal inflammatory signaling, Imp-alpha3 escorts p65 into the nucleus where it activates inflammatory gene transcription. By intercepting this process, KPV stabilizes IkB-alpha (the cytoplasmic inhibitor of NF-kB) and suppresses the nuclear translocation of p65, effectively shutting down the inflammatory cascade at one of its most central control points.
This mechanism operates at nanomolar concentrations, meaning extremely small amounts of KPV can produce meaningful anti-inflammatory effects. Importantly, KPV does not act through melanocortin receptors to inhibit NF-kB, which distinguishes it from full-length alpha-MSH and other melanocortin peptides. However, describing KPV's pathway as "receptor-independent" requires qualification: its intestinal anti-inflammatory action is specifically PepT1-dependent (Gastroenterology 2008), and PepT1 is a peptide transporter required for cellular uptake. While not a classical receptor, PepT1 dependence means KPV does not act through a purely passive or non-specific mechanism.
Melanocortin Anti-Inflammatory Signaling
Although KPV itself does not signal through classical melanocortin receptors, understanding the broader melanocortin system provides essential context for its mechanism. Alpha-MSH, from which KPV is derived, is a key effector of the melanocortin anti-inflammatory pathway. The full-length hormone binds primarily to melanocortin-1 receptor (MC1R) and melanocortin-3 receptor (MC3R), both of which are expressed on immune cells including macrophages, neutrophils, and lymphocytes.
When alpha-MSH activates these receptors, it elevates intracellular cyclic AMP (cAMP), which triggers a signaling cascade that suppresses NF-kB activation and reduces pro-inflammatory cytokine production. Research has confirmed that MC3R plays a particularly important role, as siRNA knockdown of this receptor abolished the inhibition of NF-kB signaling by alpha and gamma-MSH.
KPV appears to replicate the downstream anti-inflammatory effects of this pathway without requiring receptor binding. It directly inhibits NF-kB nuclear translocation and also reduces the activation of mitogen-activated protein kinase (MAPK) cascades, another major signaling pathway involved in inflammation. The result is suppression of the same inflammatory mediators targeted by the melanocortin receptor pathway, but through an intracellular rather than membrane-receptor-dependent mechanism.
Gut Epithelial Barrier Support
One of the most therapeutically significant aspects of KPV's pharmacology is its interaction with the intestinal peptide transporter PepT1 (SLC15A1). PepT1 is a proton-coupled oligopeptide transporter normally expressed at high levels in the small intestine, where it absorbs dietary di- and tripeptides. Critically, PepT1 expression is upregulated in the colon during inflammatory bowel disease, a change that is absent in healthy colonic tissue.
Research published in Gastroenterology demonstrated that KPV is actively transported into intestinal epithelial cells and colonic immune cells via PepT1. Once inside the cell, KPV inhibits NF-kB and MAPK signaling, reducing the production of pro-inflammatory cytokines. In mouse models of colitis induced by dextran sodium sulfate (DSS) and 2,4,6-trinitrobenzenesulfonic acid (TNBS), oral administration of KPV significantly reduced disease severity, colonic inflammation, and pro-inflammatory cytokine expression.
This PepT1 dependency was confirmed in elegant experiments using PepT1-knockout mice, in which KPV failed to produce any anti-inflammatory or anti-tumorigenic effects. The therapeutic implications are notable: KPV is preferentially taken up by inflamed intestinal tissue where PepT1 is overexpressed, providing a degree of natural targeting to diseased tissue. This also means oral administration is a viable route for gastrointestinal applications, as KPV is transported directly from the gut lumen into epithelial and immune cells without requiring systemic absorption.
Further research explored nanoparticle-based delivery systems to enhance KPV's efficacy. Hyaluronic acid-functionalized nanoparticles loaded with KPV (HA-KPV-NPs) demonstrated targeted delivery to colonic epithelial cells and macrophages. A 12,000-fold reduction in the required dose compared to free KPV has been cited in the literature (Xiao et al., 2017), though the specific sourcing and methodology behind this figure should be verified against the primary data in that publication.
Skin and Dermatological Effects
KPV has demonstrated significant anti-inflammatory activity in skin tissue across multiple research models. In mouse models of contact hypersensitivity elicited by dinitrofluorobenzene or oxazalone, both systemic (intravenous) and topical application of KPV suppressed the sensitization and elicitation phases of the immune response. Remarkably, KPV administration was also able to induce hapten-specific tolerance, meaning the treated animals did not mount an inflammatory response upon re-exposure to the same allergen.
In human keratinocyte cell models, KPV activates anti-inflammatory signaling and reduces the production of pro-inflammatory mediators. A 2025 study demonstrated that KPV mitigated fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kB pathway. Treatment with KPV restored cell viability and reduced IL-1beta secretion in keratinocytes exposed to particulate matter (PM10).
A U.S. patent (US 6,894,028) was granted for the use of KPV tripeptide in dermatological disorders, reflecting the therapeutic potential identified in preclinical research. However, KPV's high hydrophilicity and poor passive skin penetration have limited its topical application. Research into transdermal iontophoretic delivery across microporated skin has shown promise in overcoming this barrier, but clinical applications for dermatological conditions remain in early stages.
Dosage Protocols
Since KPV is not FDA-approved for human use, there are no officially established dosing guidelines. The following information reflects dosages reported in research literature and community use.
Subcutaneous Injection:
- Low dose: 100 to 200 mcg per day
- Standard dose: 200 to 500 mcg per day
- Typical cycle: 4 to 8 weeks
Oral Administration:
- Standard dose: 500 to 1,500 mcg per day
- Some protocols use divided dosing (2 times per day)
- Oral administration is preferred for gastrointestinal conditions due to PepT1-mediated uptake
Topical Application:
- Concentrations and protocols vary; limited standardization exists
- Typically formulated in creams or gels for localized skin conditions
Weight-Based Dosing: Human equivalent doses have not been formally established. Animal study doses cannot be directly extrapolated, and the optimal human dose likely varies by condition and administration route.
Cycling Guidelines:
- Common cycle length: 4 to 8 weeks
- Some users employ continuous low-dose protocols for chronic inflammatory conditions
- Cycling off periodically (2 to 4 weeks) is practiced by some to avoid potential tolerance
How to Use / Administration Methods
Subcutaneous Injection
Subcutaneous injection into the fatty tissue of the abdomen is a common administration method. This route provides systemic delivery and may be preferred for conditions involving widespread inflammation or immune modulation.
Oral Administration
Unlike most peptides, KPV is viable as an oral agent. The PepT1 transporter in intestinal epithelial cells actively absorbs the tripeptide from the gut lumen. This makes oral administration particularly well-suited for gastrointestinal conditions such as inflammatory bowel disease, where KPV is transported directly into the cells driving the local inflammatory response. Oral bioavailability is lower than injectable forms for systemic applications, but the targeted uptake in inflamed gut tissue may compensate for this limitation.
Topical Application
For skin-related conditions, topical formulations have been investigated. KPV is highly hydrophilic, which limits passive absorption through the skin barrier. Enhanced delivery methods such as iontophoresis and microporated skin have been studied to improve transdermal delivery.
Intranasal Administration
Some protocols describe intranasal administration, which may offer faster systemic absorption than oral routes and bypass first-pass metabolism. Data on this route are limited.
Results Timelines
Individual responses to KPV vary based on the condition being addressed, administration method, dosage, and individual physiology. Based on preclinical data and anecdotal reports:
Week 1 to 2:
- Potential initial reduction in inflammatory symptoms
- Some users report decreased gastrointestinal discomfort
- Mild improvements in skin inflammation may be observed
Week 2 to 4:
- More consistent anti-inflammatory effects expected
- Continued improvement in gut-related symptoms
- Skin conditions may show visible improvement
Week 4 to 8:
- Full extent of benefits typically realized within this timeframe
- Sustained reduction in inflammatory markers
- Gastrointestinal barrier function may improve
These timelines are approximations. No controlled human trials have established definitive response curves for KPV.
Research Evidence
The body of KPV research consists almost entirely of preclinical studies using cell culture and animal models. No large-scale human clinical trials have been completed.
Intestinal Inflammation: In the landmark 2008 Gastroenterology study, Dalmasso and colleagues demonstrated that KPV is transported into colonic cells via PepT1 and reduces DSS- and TNBS-induced colitis in mice. Oral KPV decreased pro-inflammatory cytokine expression and attenuated disease severity across multiple colitis models.
Colitis-Associated Cancer: A 2016 study in Cellular and Molecular Gastroenterology and Hepatology showed that KPV dramatically reduced colonic tumorigenesis in a mouse model of colitis-associated cancer. Tumor numbers, sizes, and overall burden were decreased in KPV-treated animals. This effect was abolished in PepT1-knockout mice, confirming PepT1 dependence.
Murine IBD Models: Kannengiesser and colleagues (2008) demonstrated that the melanocortin-derived tripeptide KPV had anti-inflammatory potential in two distinct murine models of inflammatory bowel disease, reducing colonic damage and inflammatory cytokine levels.
Nanoparticle Delivery: Xiao and colleagues (2017) developed hyaluronic acid-functionalized nanoparticles for oral KPV delivery. The HA-KPV-NPs achieved therapeutic efficacy at a 12,000-fold lower concentration than free KPV, while simultaneously accelerating mucosal healing and alleviating inflammation in a mouse model of ulcerative colitis.
Bronchial Inflammation: Research in human bronchial epithelial cells revealed the specific mechanism of KPV's NF-kB inhibition: nuclear import of KPV followed by competitive blocking of the Imp-alpha3/p65 interaction. This study also identified a role for MC3R agonists in melanocortin anti-inflammatory signaling.
Dermatological Research: Multiple studies have shown that KPV suppresses contact hypersensitivity in mouse models and induces hapten-specific tolerance. In keratinocyte cell cultures, KPV reduces inflammatory cytokine production and mitigates fine dust-induced cellular damage via MAPK/NF-kB pathway modulation.
Antimicrobial Activity: Alpha-MSH peptides, including KPV, have demonstrated antimicrobial effects against Staphylococcus aureus (including methicillin-resistant strains) and Candida albicans at physiological picomolar concentrations. A dimeric form ([Ac-CKPV]2) showed enhanced candidacidal activity.
Human Data: No registered clinical trials exist specifically for KPV. All evidence comes from in vitro and animal model studies, which do not guarantee equivalent effects or safety in humans.
Stacking
KPV is frequently combined with other peptides to address multiple aspects of inflammation and tissue repair simultaneously.
KPV + BPC-157
This is the most common KPV stack, combining two peptides with complementary anti-inflammatory mechanisms. BPC-157 promotes angiogenesis and tissue regeneration via VEGF pathways, while KPV targets NF-kB signaling and pro-inflammatory cytokine production. The combination is popular among users addressing gastrointestinal conditions. See our BPC-157 vs KPV comparison for a detailed breakdown.
Common Protocol:
- KPV: 200 to 500 mcg per day (subcutaneous or oral)
- BPC-157: 250 to 500 mcg per day (subcutaneous or oral)
KPV + TB-500
TB-500 (Thymosin Beta-4 fragment) provides cell migration and anti-fibrotic effects that complement KPV's anti-inflammatory properties.
KPV + GHK-Cu
GHK-Cu enhances collagen production and wound healing, while KPV addresses the inflammatory component. This combination may be explored for skin-related applications.
Other Potential Combinations:
- Thymosin Alpha-1: For broader immune modulation
- Growth hormone secretagogues: For systemic regenerative support
Reconstitution, Storage & Prep
KPV typically comes as a lyophilized (freeze-dried) powder that requires reconstitution before injectable use.
Reconstitution Process:
- Allow the KPV vial to reach room temperature
- Use bacteriostatic water (BAC water) as the reconstitution fluid
- Draw the appropriate amount of BAC water into an insulin syringe
- Inject the water slowly down the inside wall of the vial, allowing it to gently dissolve the powder
- Do not shake vigorously; gentle swirling is acceptable
- Allow the solution to sit until fully dissolved
Common Reconstitution Ratio:
- 5 mg KPV + 5 mL BAC water = 1 mg/mL (100 mcg per 0.1 mL / 10 units on an insulin syringe)
Storage Guidelines:
- Lyophilized (unreconstituted) KPV: Store at -20 degrees C for long-term storage; stable at room temperature for short periods
- Reconstituted KPV: Store at 2 to 8 degrees C (refrigerator) and use within 4 weeks
- Protect from light and avoid repeated freeze-thaw cycles
- Do not use the solution if it appears cloudy or contains particles
Side Effects
KPV has demonstrated a favorable safety profile in preclinical studies. No acute toxicity has been reported in animal models at therapeutic doses, and the peptide does not appear to broadly suppress immune function in the way that corticosteroids or other immunosuppressive drugs do.
Commonly Reported (Anecdotal):
- Mild injection site reactions (redness, tenderness)
- Mild gastrointestinal discomfort (nausea, loose stools)
- Temporary skin redness or dryness with topical application
Less Commonly Reported:
- Allergic reactions to compound ingredients (redness, hives, stinging)
- Fatigue
- Headache
Safety Advantages: Unlike many anti-inflammatory medications, KPV does not appear to increase infection risk, cause tissue thinning, or produce the metabolic side effects associated with long-term corticosteroid use. Its targeted mechanism of NF-kB inhibition may provide anti-inflammatory benefits with a narrower side effect profile than broad-spectrum immunosuppressants.
Important Limitations: Long-term human safety data do not exist. KPV products from unregulated sources carry contamination risks, and batch-to-batch variability in purity and potency is a concern. Any use should be discussed with a qualified healthcare provider.
Legal Status / FDA
KPV is not FDA-approved for any medical indication. It has historically been sold as a research chemical and cannot legally be marketed for human consumption.
Key Regulatory Points as of 2026:
- Not FDA-approved for any therapeutic indication
- No completed human clinical trials
- Previously classified under the FDA's Category 2 bulk drug substance list, restricting compounding
- In February 2026, HHS Secretary Robert F. Kennedy Jr. announced plans to reclassify approximately 14 peptides, including KPV, from Category 2 back to Category 1 status, which would permit licensed compounding pharmacies to prepare them with a valid prescription
- The formal updated FDA list had not been published at the time of writing
- Not a DEA-scheduled substance; possession is not illegal
- Available through some medical clinics and online vendors as a research compound
Even if reclassified for compounding, KPV would remain an unapproved drug without standardized dosing guidelines, formal clinical indication approval, or large-scale Phase III trial data.
Sports / WADA
KPV's status under World Anti-Doping Agency (WADA) regulations is less clearly defined than peptides like BPC-157, which is explicitly named on the Prohibited List. However, WADA's S0 category prohibits all pharmacological substances with no current approval by any governmental regulatory health authority for human therapeutic use. Because KPV is not approved for human use by any regulatory agency, it would likely fall under this blanket prohibition.
Athletes subject to anti-doping testing should consider KPV prohibited until official guidance states otherwise. As with all unapproved peptides, the risk extends beyond the substance itself to potential contaminants in unregulated products.
Conclusion
KPV represents one of the most mechanistically well-characterized anti-inflammatory peptides in preclinical research. Its ability to inhibit NF-kB signaling through a receptor-independent intracellular mechanism, its active uptake via PepT1 in inflamed intestinal tissue, and its demonstrated efficacy across multiple animal models of inflammatory bowel disease, contact dermatitis, and bronchial inflammation make it a compelling candidate for further therapeutic development.
The peptide's key advantages include its small size (enabling cost-effective synthesis), oral bioavailability for gastrointestinal applications, targeted uptake in inflamed tissue, and a side effect profile that appears favorable compared to corticosteroids and other immunosuppressive agents. For a broader look at peptides targeting gut conditions, see our [best peptides for gut health guide](/guides/best-peptides-for-gut-health).
However, the critical limitation is the complete absence of human clinical trial data. All evidence is preclinical, and animal studies do not guarantee equivalent effects or safety in humans. The lack of standardized dosing, unregulated manufacturing, and potential contamination risks in commercially available products add further uncertainty. Those considering KPV should understand they are using an experimental compound with unknown long-term effects and should consult a qualified healthcare provider before use.